Galectin-3 and sST2 in prediction of left ventricular ejection fraction after myocardial infarction

Clinica Chimica Acta

Volumn 452, Issue , 2016, Pages 50-57

  van der Velde, A Rogier ^a   Lexis, Chris P H ^a   Meijers, Wouter C ^a   van der Horst, Iwan C ^a   Lipsic, Erik ^a   Dokter, Martin M ^a   van Veldhuisen, Dirk J ^a   van der Harst, Pim ^a   de Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiac remodeling; Galectin 3; Left ventricular ejection fraction; Myocardial infarction; SST2

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CREATINE KINASE; CREATINE KINASE MB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GALECTIN 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; PLACEBO; SOLUBLE ST2; TROPONIN T; UNCLASSIFIED DRUG; CELL SURFACE RECEPTOR; GALECTIN-3, HUMAN; IL1RL1 PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR MAGNETIC RESONANCE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART FUNCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE FAILURE; HEART VENTRICLE REMODELING; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; NUCLEAR MAGNETIC RESONANCE SCANNER; PATHOGENESIS; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; BLOOD; HEART LEFT VENTRICLE FUNCTION; MIDDLE AGED; MYOCARDIAL INFARCTION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; SOLUBILITY; TIME FACTOR;

BIOMARKERS; DOUBLE-BLIND METHOD; FEMALE; GALECTIN 3; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, CELL SURFACE; SOLUBILITY; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84946600733     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.10.034     Document Type: Article

References (37)

1. Sutton M.G., Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000, 101:2981-2988. (http://www.ncbi.nlm.nih.gov/pubmed/10869273 (accessed December 15, 2014)).
2. Ohlmeier C., Mikolajczyk R., Frick J., Prütz F., Haverkamp W., Garbe E. Incidence, prevalence and 1-year all-cause mortality of heart failure in Germany: a study based on electronic healthcare data of more than six million persons. Clin. Res. Cardiol. 2015, 10.1007/s00392-015-0841-4.
3. Böhm M., Voors A.A., Ketelslegers J.-M., Schirmer S.H., Turgonyi E., Bramlage P., et al. Biomarkers: optimizing treatment guidance in heart failure. Clin. Res. Cardiol. 2011, 100:973-981. 10.1007/s00392-011-0341-0.
4. Chia S., Senatore F., Raffel O.C., Lee H., Wackers F.J.T., Jang I.-K. Utility of cardiac biomarkers in predicting infarct size, left ventricular function, and clinical outcome after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction. JACC Cardiovasc. Interv. 2008, 1:415-423. 10.1016/j.jcin.2008.04.010.
5. van der Velde A.R., Meijers W.C., de Boer R.A. Biomarkers for risk prediction in acute decompensated heart failure. Curr. Heart Fail. Rep. 2014, 11:246-259. 10.1007/s11897-014-0207-7.
6. de Boer R.A., Voors A.A., Muntendam P., van Gilst W.H., van Veldhuisen D.J. Galectin-3: a novel mediator of heart failure development and progression. Eur. J. Heart Fail. 2009, 11:811-817. 10.1093/eurjhf/hfp097.
7. Dumic J., Dabelic S., Flögel M. Galectin-3: an open-ended story. Biochim. Biophys. Acta 2006, 1760:616-635. 10.1016/j.bbagen.2005.12.020.
8. Lok D.J., Lok S.I., Bruggink-André de la Porte P.W., Badings E., Lipsic E., van Wijngaarden J., et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin. Res. Cardiol. 2013, 102:103-110. 10.1007/s00392-012-0500-y.
9. Thijssen V.L., Heusschen R., Caers J., Griffioen A.W. Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim. Biophys. Acta 2015, 1855:235-247. 10.1016/j.bbcan.2015.03.003.
10. de Boer R.A., Lok D.J.A., Jaarsma T., van der Meer P., Voors A.A., Hillege H.L., et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 2011, 43:60-68. 10.3109/07853890.2010.538080.
11. Meijers W.C., Januzzi J.L., de Filippi C., Adourian A.S., Shah S.J., van Veldhuisen D.J., et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am. Heart J. 2014, 167:853-60.e4. 10.1016/j.ahj.2014.02.011.
12. Lok D.J.A., Van Der Meer P., de la Porte P.W.B.-A., Lipsic E., Van Wijngaarden J., Hillege H.L., et al. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin. Res. Cardiol. 2010, 99:323-328. 10.1007/s00392-010-0125-y.
13. Chen A., Hou W., Zhang Y., Chen Y., He B. Prognostic value of serum galectin-3 in patients with heart failure: a meta-analysis. Int. J. Cardiol. 2015, 182:168-170. 10.1016/j.ijcard.2014.12.137.
14. de Boer R.A., van Veldhuisen D.J., Gansevoort R.T., Muller Kobold A.C., van Gilst W.H., Hillege H.L., et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 2012, 272:55-64. 10.1111/j.1365-2796.2011.02476.x.
15. Ho J.E., Liu C., Lyass A., Courchesne P., Pencina M.J., Vasan R.S., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60:1249-1256. 10.1016/j.jacc.2012.04.053.
16. Weinberg E.O., Shimpo M., De Keulenaer G.W., MacGillivray C., Tominaga S., Solomon S.D., et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation 2002, 106:2961-2966. (http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1460012&tool=pmcentrez&rendertype=abstract (accessed December 15, 2014)).
17. Bartunek J., Delrue L., Van Durme F., Muller O., Casselman F., De Wiest B., et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J. Am. Coll. Cardiol. 2008, 52:2166-2174. 10.1016/j.jacc.2008.09.027.
18. Demyanets S., Kaun C., Pentz R., Krychtiuk K.A., Rauscher S., Pfaffenberger S., et al. Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J. Mol. Cell. Cardiol. 2013, 60:16-26. 10.1016/j.yjmcc.2013.03.020.
19. Truong Q.A., Januzzi J.L., Szymonifka J., Thai W., Wai B., Lavender Z., et al. Coronary sinus biomarker sampling compared to peripheral venous blood for predicting outcomes in patients with severe heart failure undergoing cardiac resynchronization therapy: the BIOCRT study. Heart Rhythm. 2014, 11:2167-2175. 10.1016/j.hrthm.2014.07.007.
20. Dieplinger B., Mueller T. Soluble ST2 in heart failure. Clin. Chim. Acta 2015, 443C:57-70. 10.1016/j.cca.2014.09.021.
21. Friões F., Lourenço P., Laszczynska O., Almeida P.-B., Guimarães J.-T., Januzzi J.L., et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin. Res. Cardiol. 2015, 104:491-499. 10.1007/s00392-015-0811-x.
22. Shimpo M., Morrow D.A., Weinberg E.O., Sabatine M.S., Murphy S.A., Antman E.M., et al. Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 2004, 109:2186-2190. 10.1161/01.CIR.0000127958.21003.5A.
23. Gaggin H.K., Januzzi J.L. Biomarkers and diagnostics in heart failure. Biochim. Biophys. Acta 2013, 1832:2442-2450. 10.1016/j.bbadis.2012.12.014.
24. Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology foundation/American heart association task force on practice guidelines. J. Am. Coll. Cardiol. 2013, 62:e147-e239. 10.1016/j.jacc.2013.05.019.
25. Weir R.A.P., Petrie C.J., Murphy C.A., Clements S., Steedman T., Miller A.M., et al. Galectin-3 and cardiac function in survivors of acute myocardial infarction. Circ. Heart Fail. 2013, 6:492-498. 10.1161/CIRCHEARTFAILURE.112.000146.
26. Weir R.A.P., Miller A.M., Murphy G.E.J., Clements S., Steedman T., Connell J.M.C., et al. Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. J. Am. Coll. Cardiol. 2010, 55:243-250. 10.1016/j.jacc.2009.08.047.
27. Lexis C.P.H., van der Horst I.C.C., Lipsic E., Wieringa W.G., de Boer R.A., van den Heuvel A.F.M., et al. Effect of metformin on left ventricular function after acute myocardial infarction in patients without diabetes: the GIPS-III randomized clinical trial. J. Am. Med. Assoc. 2014, 311:1526-1535. 10.1001/jama.2014.3315.
28. Lexis C.P.H., van der Horst I.C.C., Lipsic E., van der Harst P., van der Horst-Schrivers A.N.A., Wolffenbuttel B.H.R., et al. Metformin in non-diabetic patients presenting with ST elevation myocardial infarction: rationale and design of the glycometabolic intervention as adjunct to primary percutaneous intervention in ST elevation myocardial infarction (GIPS)-III trial. Cardiovasc. Drugs Ther. 2012, 26:417-426. 10.1007/s10557-012-6413-1.
29. Meijers W.C., van der Velde A.R., de Boer R.A. The ARCHITECT galectin-3 assay: comparison with other automated and manual assays for the measurement of circulating galectin-3 levels in heart failure. Expert. Rev. Mol. Diagn. 2014, 14:257-266. (http://www.ncbi.nlm.nih.gov/pubmed/24606321).
30. Christenson R.H., Duh S.-H., Wu A.H.B., Smith A., Abel G., de Filippi C.R., et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin. Biochem. 2010, 43:683-690. 10.1016/j.clinbiochem.2010.02.001.
31. Mueller T., Dieplinger B. The Presage(®) ST2 assay: analytical considerations and clinical applications for a high-sensitivity assay for measurement of soluble ST2. Expert. Rev. Mol. Diagn. 2013, 13:13-30. 10.1586/erm.12.128.
32. Manzano-Fernández S., Januzzi J.L., Pastor-Pérez F.J., Bonaque-González J.C., Boronat-Garcia M., Pascual-Figal D.A., et al. Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure. Cardiology 2012, 122:158-166. 10.1159/000338800.
33. Kruk M., Menon V., Kądziela J., Sadowski Z., Ruz˙yłło W., Janas J., et al. Impact of percutaneous coronary intervention on biomarker levels in patients in the subacute phase following myocardial infarction: the occluded artery trial (OAT) biomarker ancillary study. BMC Cardiovasc. Disord. 2013, 13:91. 10.1186/1471-2261-13-91.
34. Sanchez-Mas J., Lax A., Asensio-Lopez M.C., Fernandez-Del Palacio M.J., Caballero L., Garrido I.P., et al. Galectin-3 expression in cardiac remodeling after myocardial infarction. Int. J. Cardiol. 2014, 172:e98-e101. 10.1016/j.ijcard.2013.12.129.
35. van der Velde A.R., Gullestad L., Ueland T., Aukrust P., Guo Y., Adourian A., et al. Prognostic value of changes in galectin-3 levels over time in patients with heart failure: data from CORONA and COACH. Circ. Heart Fail. 2013, 6:219-226. 10.1161/CIRCHEARTFAILURE.112.000129.
36. Yu L., Ruifrok W.P.T., Meissner M., Bos E.M., van Goor H., Sanjabi B., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 2013, 6:107-117. 10.1161/CIRCHEARTFAILURE.112.971168.
37. Lax A., Sanchez-Mas J., Asensio-Lopez M.C., Fernandez-Del Palacio M.J., Caballero L., Garrido I.P., et al. Mineralocorticoid receptor antagonists modulate galectin-3 and interleukin-33/ST2 signaling in left ventricular systolic dysfunction after acute myocardial infarction. JACC Heart Fail. 2015, 3:50-58. 10.1016/j.jchf.2014.07.015.